| scholarly article | Q13442814 |
| P50 | author | Andrew James McMichael | Q21165187 |
| P2093 | author name string | Sandip Patel | |
| Edmund G-T Wee | |||
| Tomás Hanke | |||
| P433 | issue | Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Kenya | Q114 |
| P304 | page(s) | 75-80 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Journal of General Virology | Q6295245 |
| P1476 | title | A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques | |
| P478 | volume | 83 |
| Q27484994 | A Heterologous DNA Prime-Venezuelan Equine Encephalitis Virus Replicon Particle Boost Dengue Vaccine Regimen Affords Complete Protection from Virus Challenge in Cynomolgus Macaques |
| Q27024614 | A global approach to HIV-1 vaccine development |
| Q80861363 | Augmentation of SIV DNA vaccine-induced cellular immunity by targeting the 4-1BB costimulatory molecule |
| Q58661772 | Cellular immune responses to helper-free HSV-1 amplicon particles encoding HIV-1 gp120 are enhanced by DNA priming |
| Q35852348 | Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know |
| Q38581981 | DNA Immunization for HIV Vaccine Development |
| Q58711069 | DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination |
| Q33208276 | DNA vaccines and their application against parasites--promise, limitations and potential solutions. |
| Q37195521 | Delivery strategies for novel vaccine formulations |
| Q40551477 | Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa |
| Q34647872 | Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. |
| Q37079841 | Experimental vaccines in animal models for schistosomiasis |
| Q81155956 | Flow cytometric analysis of human antigen-specific T-cell proliferation |
| Q41579160 | Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys |
| Q35166836 | HIV vaccines 1983-2003. |
| Q37428013 | HIV vaccines under study |
| Q38956398 | HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. |
| Q34726113 | HIV/AIDS treatment and HIV vaccines for Africa |
| Q26799624 | HIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategies |
| Q35078281 | Identification of CD8+ cytotoxic T lymphocyte epitopes from porcine reproductive and respiratory syndrome virus matrix protein in BALB/c mice |
| Q45710911 | Immunization with Th-CTL Fusion Peptide and Cytosine-Phosphate-Guanine DNA in Transgenic HLA-A2 Mice Induces Recognition of HIV-Infected T Cells and Clears Vaccinia Virus Challenge |
| Q37804532 | Immunologic Basis of Vaccine Vectors |
| Q44364556 | Inclusion of the viral anti-apoptotic molecule M11L in DNA vaccine vectors enhances HIV Env-specific T cell-mediated immunity. |
| Q39876175 | Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay |
| Q34142869 | Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen |
| Q39028785 | Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c |
| Q45730049 | Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya |
| Q36055506 | Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants |
| Q35159094 | New gene-based approaches for an AIDS vaccine |
| Q37924090 | New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials |
| Q42795896 | Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 Gag. |
| Q33877458 | Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques |
| Q38675720 | Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. |
| Q42738025 | Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques |
| Q38876358 | Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa |
| Q62129133 | Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques |
| Q90479100 | T cell-based strategies for HIV-1 vaccines |
| Q37333743 | T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces |
| Q40616719 | The HIV-1 chimeric protein CR3 expressed by poxviral vectors induces a diverse CD8+ T cell response in mice and is antigenic for PBMCs from HIV+ patients. |
| Q34764822 | Therapeutic vaccination against chronic viral infections |
| Q52005669 | Use of interleukin 15 to enhance interferon-gamma production by antigen-specific stimulated lymphocytes from rhesus macaques. |
Search more.